Biotoxtech Co., Ltd. announces an Equity Buyback in the amount of KRW1000 mm
April 08, 2012
Share
The Board of Directors of Biotoxtech Co., Ltd. (KOSE:A086040) authorized a share repurchase program on April 9, 2012. Under the program, the company will repurchase up to KRW 1 billion worth own shares pursuant to a trust agreement with SK Securities Co., Ltd. The purpose behind the program is to stabilize the stock price and to enhance shareholder value. Repurchases will commence on April 12, 2012 and will continue until October 11, 2012. As of April 8, 2012, the company has no shares in treasury. SK Securities Co., Ltd. acted as the broker to the company for the buyback.
Biotoxtech Co., Ltd. is a Korea-based company engaged in the research of non-clinical evaluation business. The Company provides safety evaluation research, efficacy evaluation research and analysis research. Its safety evaluation research business provides general toxicity tests, local toxicity tests, reproductive and development tests, genotoxicity tests, immunotoxicity tests, carcinogenicity tests, safety pharmacology tests, ecotoxicology tests, histopathology tests and hematology tests. Its efficacy evaluation research business provides efficacy evaluation of medical supplies, health supplements and cosmetics. Its analysis research business provides pharmacokinetics (PK) tests and toxicokinetics (TK) tests services, as well as validation and bio analysis services. On March 13, 2013, the Company acquired a 60% stake in its new established subsidiary.
BIOTOXTECH CO., LTD. 
